Attracting experts working in all areas of nonalcoholic steatohepatitis,
the conference will examine the latest research and development in
pathogenesis, diagnosis, and treatment of the disease.
An increasing number of people are being diagnosed with the nonalcoholic
fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year,
and the primary method of treatment is weight loss. With no approved medicines
on the market, the drug development race is intensifying. The pathogenesis of
NASH is still not fully understood, and definitive diagnostic methods are
invasive, so development has been slow.
There are, however, promising developments in research that will
hopefully bolster drug development and other methods of treatment. Examples of
such developments include improved in vivo liver models, non-invasive
diagnostic biomarkers and a better understanding of the disease’s mechanisms.
This year’s congress will focus on these exciting advancements, as well as on
the challenges of preclinical and clinical research in NASH. There will also be
a session on business development/regulation and a showcase of the most promising
therapeutics in development.